Marijuana, Inc. operates as a shell company seeking to merge with another entity with experienced management and opportunities for growth. The company is headquartered in Saint Petersburg, Florida. The company went IPO on 2010-12-28. The firm's mammalian exosomal technology platform has shown the capability to increase the efficacy of Merck's drug Temozolomide (TMZ) in the treatment of glioblastoma (GBM). Its patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The firm's proprietary loading technology can infuse a range of molecules from drugs to deoxyribonucleic acid (DNA).
P/E (price / listing EPS) Forward revenue growth (NTM)